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Combined activity of COX-1 and COX-2 is
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Mattias Salling Dahllöf2, Steen Seier Poulsen2, Mark Berner Hansen1 and Niels Bindslev2
Abstract
Background: Cyclooxygenase (COX) activity is increased in endoscopic normal colonic mucosa from patients with
colorectal neoplasia (CRN). COX-2 is thought to be the predominant COX isozyme involved in neoplasia. Meanwhile,
relative contributions of COX-1 and COX-2 isoforms are unknown. Knowledge about their mutual activity in colonic
mucosa is important for diagnostics and targeted therapy for CRN. The aim of this study was to assess the relative
function, expression and localization of COX-1 and COX-2 enzymes in colonic non-neoplastic human mucosa and
thereby to potentially reveal a mucosal disease predisposition for better treatment.
Methods: Biopsies were pinched from normal appearing colonic mucosa in patients undergoing endoscopy. Ussing
chamber technique was applied for an indirect assessment of epithelial activity, RT-qPCR for expression and
immunohistochemistry for localization of COX-1 and COX-2 enzymes in patients without (ctrls) and with a history
of CRN (CRN-pts).
Results: Combined COX-1 and COX-2 activity was higher in CRN-pts, p = 0.036. COX-2 was primarily localized in
absorptive cells, while COX-1 appeared to be restricted to nonenteroendocrine tuft cells of the colonic epithelium.
Conclusions: In biopsies from endoscopic normal appearing colonic mucosa, combined activity of COX-1 and COX-2
enzymes is increased in CRN-pts compared with ctrls. This indicates that COX-1 and COX-2 together contribute to an
increased proliferation process. Of note, in colonic epithelial cell lining, the COX-1 enzyme seems localized in tuft cells.
Keywords: Short circuit current (SCC), Cyclooxygenase, Endoscopic, Biopsy, Carcinogenesis, Tuft cells
Background
In the Western world, colorectal cancer (CRC) caused
some 694,000 deaths in 2012, making it the third most
common type of cancer and the second leading cause of
cancer-related death [1]. Observation and documenta-
tion of possible altered signaling in pre-neoplastic colo-
rectal mucosa from humans are essentials for future
development of targeted pharmacotherapy against CRC
and colorectal neoplasia (CRN).
Epidemiological studies show that daily intake of non-
steroidal anti-inflammatory drugs (NSAIDs) reduces
long-term incidence of developing CRC [2, 3]. Based
primarily on these data, the United States Preventive
Services Task Force (USPSTF) recently recommended
routine use of low-dose aspirin for chronic disease
prophylaxis, including CRC prevention, among adults
between ages 50 and 59 with a > 10% risk of cardiovascu-
lar events [4, 5].
The mechanism behind NSAIDs’s chemoprevention is
most likely due to inhibition of cyclooxygenase (COX)
enzymes, although other mechanisms of aspirins
CRN-prevention are possible [6]. COX enzymes convert
arachidonic acid into various metabolites including pros-
taglandin E2 (PGE2). PGE2 appears to be involved in
neoplastic changes owing to its proinflammatory proper-
ties. Further, PGE2 has been demonstrated to promote
proliferation, cell migration, angiogenesis and reduce
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apoptosis in colonic mucosal lining [7, 8]. The COX en-
zyme exists in two major and clinically relevant
isoforms: COX-1 and COX-2. COX-1 is known to have
constitutive activity, while COX-2 is an infectious and
injury-inducible enzyme.
Our research group has previously identified up-
regulated indomethacin-sensitive COX activity in biop-
sies taken from endoscopically normal appearing colonic
mucosa when compared between patients with a history
of or present CRN to controls [9]. Another study by us
showed a significantly augmented expression of two po-
tential PGE2 inward transporters, OATP2B1 and
OATP4A1, in colonic biopsies from patients with CRN
compared to patients without CRN. This up-regulated
expression points to a compensatory increased basolat-
eral PGE2 uptake into colonic columnar epithelial cells
associated with neoplasia [10]. This study also suggested
the ABCC5 transporter as the epithelial cell PGE2 ex-
porter rather than the ABCC4 transporter.
The importance of COX enzyme subtypes for develop-
ment of CRC is generally assumed to be due to an in-
creased activity of the COX-2 isozyme [11]. However,
this view is mostly based on studies on transformed cells
or malignant tissue samples. It is well-known that the
expression and activity of effector molecules, such as en-
zymes, transporters and receptors, often are dramatically
altered in cell lines and in cancerous tissues as a bypro-
duct of the cancer process itself. So far, to our know-
ledge, the relative contribution of COX-1 and COX-2
subtypes to an up-regulated COX activity, causing CRN,
has not yet been fully elucidated. Accordingly, we
decided to determine possible altered activity of both
COX-1 and COX-2 in endoscopically normal appearing
colonic mucosa from individuals with CRN when com-
pared to controls. Choosing a comparison between
normal appearing mucosa from both patient groups, fur-
ther give a potential opportunity to evaluate if the
colonic mucosa in patients with CRN is predisposed for
development of the disease.
We hypothesized that activity of both COX isozymes
might be up-regulated even in normal appearing mucosa
and thereby together contribute to development of CRN,
Fig. 1.
Accordingly, the aim of this study was to assess the
relative functional importance, expression and
localization of COX-1 and COX-2 enzymes in endoscop-
ically normal appearing colonic mucosa from patients
without (ctrls) and with colorectal neoplasia (CRN-pts),
and furthermore to potentially reveal a mucosal predis-
position for the disease.
Methods
Study population
Adult patients (≥ 18 years), referred for colonoscopy,
were invited to participate. Patients were pooled into the
neoplasia group if they presented a history of CRN.
Patients with no present endoscopic signs or history of
CRN served as ctrls. Patients with hemorrhagic diathesis
or inflammatory bowel disease were excluded from the
study. For each patient, we noted medication, body mass
index (BMI), previous illnesses, all signs of earlier colo-
rectal disease and the findings during the colonoscopy.
Fig. 1 A simplified scheme for involvement of COX enzymes in development of CRN. COX-1 and COX-2 convert active arachidonic acid (AAA)
into PGE2, which at the basolateral side is transported out off the cell via an ABCC5-transporter. Through a Gs-protein-coupled EP-4-receptor,
PGE2 mediates conversion of ATP to cAMP, thus inducing mucosal Cl
− secretion and cell proliferation. COX isozymes may be inhibited selectively
by SC-560 and celecoxib or non-selectively by indomethacin. Pathways with markers are hypothetically increased in CRN, thereby increasing
cell proliferation and carcinogenesis. PGE2: prostaglandin E2, cAMP: cyclic adenosine monophosphate, AMP: adenosine monophosphate, ATP: adeno-
sine triphosphate, COX: cyclooxygenase, CRN: colorectal neoplasia, Gs: stimulatory heterotrimeric G protein, ABCC5: ATP-binding cassette transporter
C5, EP4: prostaglandin receptor subtype 4, SC-560: selective COX-1 inhibitor, celecoxib: selective COX-2 inhibitor
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Forty three patients were enrolled in the study
(19 women). For Ussing chamber studies, biopsies from
randomly selected 22 CRN-pts (10 women) and 21 ctrls (9
women) were examined. In the real time polymerase chain
reaction study (RT-qPCR), biopsies from randomly selected
11 CRN-pts (6 women) and 7 ctrls (4 women) were
included. For immunohistochemistry, biopsies from
randomly selected 8 CRN-pts (3 women) and 7 ctrls (3
women) were assessed. Eleven patients, both CRN-pts
(2 women, 3 men) and ctrls (3 women, 3 men), had co-
morbidity such as diabetes, hypertension, atrial fibrilla-
tion, prostatic cancer, chronic obstructive pulmonary
disease and dyslipidemia.
The study protocol was approved by the scientific
Ethical Committee of Copenhagen (H-3-2013-107) and
the Danish Data Protection Agency approved the study
protocol (BBH-2013-024, I-suite no: 02342). The study
was conducted in accordance with the Helsinki declar-
ation. Patient information and data were collected and
stored in locked containers.
Statistical analysis
Mann-Whitney Rank Sum test or unpaired t-test was
used for the calculation of p-values depending on the re-
sults of normality and equal variance tests. P-values less
than 0.05 were considered significant. All statistics were
done with SigmaPlot 12.3 for Windows (Systat Software
Inc., USA/Canada). Data are presented as mean (±SEM).
Chemicals
Theophylline, indomethacin, prostaglandin E2 (PGE2),
SC-560 and celecoxib were purchased from Sigma-
Aldrich (Seelze, Germany). Amiloride, bumetanide and
ouabain were purchased from Sigma (Vallensbaek
Strand, Denmark).
The antibody for COX-2 (cat. no.: SB-M3210) was
obtained from Nordic BioSite ApS (Täby, Sweden) and
antibodies for COX-1 from Santa Cruz Biotechnology
(cat. no.: sc-1752, sc-7950, and sc-19998; Santa Cruz, CA,
USA) and Abcam Cambridge (cat. no.: ab109025;
Cambridge, UK). Fluorescence double labeling was
conducted with antibodies for the following entities:
serotonin (cat. no.: M075801-2) and chromogranin A (cat.
no.: M086929-2) were purchased from Dako (Glostrup,
Denmark); proprotein convertase-1 and -2 (PC1 and PC2;
cat. no.: alx-210-518-R100 and alx-210-519-R100) from
Enzo Life Sciences (Varazdin, Croatia); somatostatin (cat.
no.: sc-13099) from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); gastric inhibitory polypeptide (GIP, cat.
no.: ABS021-04-02) from Thermo Scientific (Rockford,
USA) and glucagon-like peptide-1 (GLP-1; cat. no.: 87805-
34) from Tocris Bioscience (Bristol, UK).
Primer sequences were synthesized by TAG
Copenhagen (Copenhagen, Denmark). All other chemi-
cals were of analytical grade.
Biopsy procedure
Six biopsies were obtained from each patient. Of the six
biopsies, one was used for RT-qPCR, one for immuno-
histochemistry and four biopsies were mounted in modi-
fied air-suction Ussing chambers [9]. During endoscopy,
biopsies were pinched from normal appearing mucosa
approximately 30 cm orally from the anal verge and at
least 10 cm from abnormal tissue on retraction of the
endoscope. Standard biopsy forceps (Boston Scientific,
Radial Jaw 4, outside diameter of 2.2 mm) were used.
Biopsies were placed in iced Ringer-solution and imme-
diately transferred to the laboratory for mounting in
Ussing chambers.
Three experimental techniques were employed:
Ussing chamber (A), RT-qPCR (B) and immunohisto-
chemistry (C)
A. Functional studies
Biopsies were mounted within 30 min in Ussing cham-
bers [9]. Mounting was carried out at 10 times magnifi-
cation by means of a stereomicroscope to secure correct
mucosa-serosa orientation and proper fixation. Both
sides of the tissue were bathed in bicarbonate-Ringer
solution containing (in mM) 140 Na+, 4 K+, 121 Cl−, 1
Ca2+, 0.5 Mg2+, 0.5 SO4
2−, 25 HCO3
−, and 5.5 D-glucose.
Solutions were oxygenated with 95% O2/5% CO2, i.e.,
buffered to pH 7.4, and circulated by gas-lifts.
Temperature was maintained at 37 °C by water jackets.
Short circuit current (SCC, μA·cm− 2) and slope con-
ductance (G, mS·cm− 2) were recorded continuously
using an automated voltage-clamp device. Correction for
solution resistance was performed immediately before
specimens were mounted. The slope conductance was
only used as a control for acceptable slit fixation ranging
between 60 and 120 mS per sq. cm.
Experiments were initiated following a minimum
equilibration period of 10 min. Amiloride (20 μM, apical
side) was added to inhibit sodium channels (ENaCs).
Theophylline (400 μM, both sides) was then added to
raise the level of cAMP due to inhibition of phospho-
diesterase activity and thus optimizing the effect of COX
subtype inhibitors. When the SCC was stable, a selective
inhibitor of either COX-1 (SC-560, 500 nM, both sides)
or COX-2 (celecoxib, 500 nM, both sides) was added.
After 30 min or when the SCC reached a plateau, indo-
methacin was added (13 μM, both sides). Again, after
30 min or when SCC had stabilized, PGE2 (100 nM,
serosal side) was added. Finally, at the end of the experi-
ment, bumetanide (25 μM, serosal side) was added as a
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measure for induced chloride secretion and followed by
ouabain (200 μM, serosal side) as a control of biopsy via-
bility. Selection of half-chamber concentrations for the
various drugs was based on pharmacodynamic experi-
ence from previous studies.
B. Expression studies
From each patient included here, one biopsy was
obtained and immediately transferred to RNAlater (Life
Technologies, Naerum, Denmark). Biopsies were ho-
mogenized using a TissueLyser II (Qiagen, Copenhagen,
Denmark), and subsequently RNA was extracted using
NucleoSpin RNA® (Macherey-Nagel, Düren, Germany).
Concentration and purity of RNA were determined
using a NanoDrop® ND-1000 (NanoDrop Technologies,
Wilmington, DE, USA), the latter by the A260/A280 and
A260/A230 absorbance ratios. RNA was converted to
cDNA using the iScript™ cDNA Synthesis Kit (BioRad,
Copenhagen, Denmark) according to the manufacturer’s
protocol. Primers against genes of interest and ß-actin
were designed using Primer3 (http://frodo.wi.mit.edu/
primer3/input.htm) based on sequences obtained from
Ensembl (www.ensembl.org). The primer sequences
were synthesized by TAG Copenhagen (Copenhagen,
Denmark): COX-1 forward (5’-GAGCAGCTTTTCCAG
ACGA -3′); COX-1 reverse (5′- TCCTCGATGACAATC
TTGATG -3′); COX-2 forward (5′- ACTAGAGCCCTT
CCTCCTGTG -3′); COX-2 reverse (5′- GGGATCAGG
GATGAACTTTCT -3′); ß-Actin forward (5’-ACCCAG
CACAATGAAGATCA-3′); ß-Actin reverse (5’-CGTCA
TACTCCTGCTTGCTG-3′). Dilution series of cDNA
from HEK293 cells were run to verify acceptable amplifi-
cation efficiencies and specificities by standard and
dissociation curves for all primer sets. cDNA was ampli-
fied on a 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) using Fast SYBR®
Green Master Mix (Applied Biosystems) in accordance
with the manufacturer’s manual. Samples were run in
triplicates with ß-actin primers as reference gene on all
plates. Results were analyzed using SDS 2.3 (Applied
Biosystems), and expression was calculated by the 2-ΔCT
method.
C. Localization and abundance studies
Immunohistochemical staining was performed to
localize and quantify the two COX isoforms. One co-
lonic biopsy from each patient, included for this part,
was put aside in 4% neutral buffered formaldehyde right
after the endoscopy procedure. Biopsies were subse-
quently embedded in paraffin and cut in 4 μm thin
slices. The sections were deparaffinated and rehydrated,
followed by heat treatment in a microwave oven in order
to unmask epitopes. The sections were blocked with a
2% bovine serum albumin solution for 10 min to rule
out unspecific antibody adhesion, followed by incubation
with a primary antibody at 4 °C overnight. Images were
recorded using a Zeiss Axioplan 2 plus microscope
(Jena, Germany) fitted with a Photometrics CoolSNAP
camera (Tucson, AZ, USA) and analysis was performed
using Image-Pro Plus 7.0 software.
Immunohistochemical staining of COX-1 turned out
insufficient for three of the antibodies and a fourth
(sc-1752) stained single, open enteroendocrine-like cells
in the epithelium, Fig. 3. To verify that the coloring was
of non-enteroendocrine cells, double labeling immuno-
fluorescence with sc-1752 and various markers for endo-
crine cells was performed. The following antibody
concentrations were used: COX-1 (sc-1752) 1:800,
COX-2 1:400, GLP-1 1:375, serotonin 1:100, somato-
statin 1:2500, PC1 1:1250, PC2 1:1600, chromogranin A
1:10000 and GIP 1:1750.
For COX-2, all biopsies were quantified by a blinded
investigator. Quantification images were recorded at 20×
magnification and the area measured represented
186,000 μm2 of the tissue. The area of stained structures
was quantified by selecting a colored region of interest.
Automatically, areas with same color were measured.
One image from each biopsy was measured. Blinded
quantification of COX-2 was repeated 3 times. Data
were calculated as mean area μm2 ± SEM for each group.
Images for localization were recorded using a Zeiss
Axio10 Imager A1 microscope (Jena, Germany) fitted
with a Zeiss AxioCam ICc 3 camera (Jena, Germany)
and analysis was performed using Image-Pro 9.1 soft-
ware. Only mucosal layers were analyzed.
Results
Study population
We found no differences in comorbidity or in medica-
tion between the two patient groups. BMI and age was
higher in CRN-pts compared to ctrls with BMI display-
ing statistically significance (BMI: CRN-pts 27.2 (±1.2)
vs ctrls 23.2 (±1.2), p = 0.048. Age: CRN-pts 69.5 (±4.1)
years vs ctrls 58.4 (±5.4) years, p = 0.062).
A. Function
Baseline SCC and differential effects of amiloride,
theophylline, indomethacin, PGE2, bumetanide and oua-
bain on SCC are listed in Table 1. Inhibition of SCC by
amiloride was more pronounced in CRN-pts compared
to ctrls, p = 0.006. Stimulation of SCC by theophylline
was significantly more efficacious in CRN-pts compared
to ctrls, p = 0.025.
Total SCC response to COX inhibition was calculated
by adding the response of either selective inhibitor to
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the ensuing response of indomethacin. The decrease in
SCC to either of the selective COX-inhibitors was nor-
malized based on total COX inhibition for the individual
biopsy. Examples of Ussing chamber experiments of in-
hibition of either COX subtype can be seen in Fig. 2. No
difference in SCC inhibition between patients group
was observed for either of the two selective COX
inhibitors. By contrast, the SCC response of combined
COX-1 and COX-2 inhibition, after indomethacin
application, was significantly larger in CRN-pts com-
pared to ctrls, p = 0.036, Table 1. This significant data
difference corroborates a significantly larger drop in
Table 1 Drug-induced changes in short circuit current (SCC)
CRN-pts
Mean ΔSCC, SEM (μA·cm− 2)
CRN-pts
N/n
Ctrls
Mean ΔSCC, SEM (μA·cm− 2)
Ctrls
N/n
p-value
Baseline SCC 91 ± 10.1 22/42 95 ± 26.6 21/30 0.518
Amiloride −77 ± 13.4 17/38 −30 ± 15.1 13/22 0.006 *
Theophylline 73.5 ± 7.1 17/38 50.5 ± 6.9 13/22 0.025 *
SC-560 + Celecoxib −66.7 ± 3.5 17/38 −54.7 ± 4.3 13/22 0.036 *
PGE2 87.5 ± 32.3 15/26 73.0 ± 17.3 10/19 0.275
Bumetanide −41.5 ± 5.3 15/32 −55.0 ± 9.4 7/18 0.261
Ouabain −70.5 ± 14.4 13/24 −93.0 ± 14.7 7/18 0.431
Baseline SCCs are absolute values, while amiloride (20 μM, apical), theophylline (400 μM, both sides), SC-560 + Celecoxib (500 μM, both sides), prostaglandin
(PGE2) (100 nM, serosal), bumetanide (13 μM, serosal) and ouabain (200 μM, serosal) effects are changes from prestimulatory SCC (ΔSCC). SC-560 and Celecoxib
are selective COX-1 and COX-2 inhibitors. SC-560 + Celecoxib represent the combined SCC inhibition data of both COX-1/indomethacin and COX-2/indomethacin
application. CRN-pts values represent SCC or ΔSCC in biopsies from colorectal neoplasia patients and ctrls values are for patients without colorectal neoplasia. N=number of
patients, n=number of biopsies, in parenthesis (N/n). * p-value < 0.05
Fig. 2 Examples of typical recording in Ussing Chamber experiments on short circuit current (SCC) following exposure to COX-1 (cyclooxygenase)
inhibitor SC-560 (a) and COX-2 inhibitor celecoxib (b). Compounds were added to biopsies in the following concentrations: amiloride (20 μM,
mucosal side), theophylline (400 μM, both sides), either COX-1 inhibitor (SC-560, 500 nM, both sides) or COX-2 inhibitor (celecoxib, 500 nM, both
sides), indomethacin (13 μM, both sides) and prostaglandin (PGE2, 100 nM, serosal side)
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SCC to indomethacin found in a previous study for
CRN-pts compared to ctrls [9].
When comparing the fractional contribution of
COX-1 and COX-2, both normalized with total COX ac-
tivity, COX-1 contribution was significantly higher com-
pared to COX-2 both for ctrls (p = 0.028) and CRN-pts
(p = 0.035), Table 2.
B. Expression
Using RT-qPCR, we examined the expression of COX-1
and COX-2 in colonic mucosa from CRN-pts and ctrls.
We further wanted to compare the combined expression
of COX-1 and COX-2 between the two patient groups.
The expression of COX-1 was significantly higher
compared to COX-2 both in CRN-pts (COX-1 = 0.024
(±0.003) vs COX-2 = 0.007 (±0.002), p = 0.012) and in
ctrls (COX-1 = 0.020 (±0.003) vs COX-2 = 0.005
(±0.002), p < 0.001). Comparing CRN-pts with ctrls,
mRNA-expression of both COX-1 and COX-2 was nu-
merically higher in CRN-pts, although upregulation of
both genes failed to reach statistical significance
(COX-1: p = 0.249, COX-2: p = 0.431), Table 3. Com-
bined expression of the COX isozymes was defined as
the summed expression of COX-1 and COX-2.
Comparing combined COX expression for CRN-pts and
ctrls showed no statistical significant difference (CRN-
pts = 0.015 (±0.003) vs ctrls = 0.012 (±0.003), p = 0.353).
C. Localization and abundance
Localization of COX-2 was immunohistochemically
delimited to cytoplasm of absorptive cells, Fig. 3a. Quan-
tification of COX-2 showed no significant difference be-
tween CRN-pts and ctrls, CRN-pts: 1472 ± 168 μm2 and
ctrls: 1398 ± 132 μm2, p = 0.362.
Since neither of the classical makers for endocrine cells
co-stained with sc-1752 for the COX-1 enzyme, we con-
clude that the sc-1752 antibody marks tufts cells in the
epithelial lining as also reported by Gerbe et al. ([12], and
their supplemental material Fig. S1A). Use of two other
antibodies gave either smeared stains or no staining.
Double fluorescence staining was made with COX-1
antibody sc-1752 and antibodies for the following endo-
crine cell-markers: chromogranin A, GIP, serotonin,
GLP-1, somatostatin, PC1 and PC2. None of the markers
for endocrine cells were found to co-localize with
COX-1, see Fig. 3c, thus confirming the coloring of non-
enteroendocrine epithelial cell, identified as tuft cells,
and also of unspecified solitary stromal cells. In a pre-
liminary enhanced fluorescence immuno-histochemical
study of COX-1 in human colonic biopsies in our
laboratory, there is a clear subepithelial localization of
the protein in solitary cells with a morphology resem-
bling myofibroblasts (Dr. Hanne Borger Rasmussen and
Christian Hunnicke Petersen, unpublished results).
Discussion
Our study seeks to evaluate parameters related to the con-
tent and impact of PGE2 in normal human colonic mu-
cosa. We chose to study normal appearing colonic
mucosa from ctrls and CRN-pts in order to try to evaluate
a possible predisposition for the disease in normal tissue
from CRN-pts when compared with ctrls. Thus, in biop-
sies from this mucosa, we looked at a functional param-
eter, indomethacin-sensitive short circuit current (IS-SCC)
in the presence of amiloride, including COX enzyme
subtype-specific SCC inhibition. Although IS-SCC is indir-
ectly related to the effects of PGE2, it is well-established as
a measure of PGE2 activity working through a COX
enzyme-adenylate-cyclase-Gs-cAMP pathway, Fig. 1.
There are several advantages of IS-SCC, as a measure of
functionality. Thus, IS-SCC is solely related to the epithe-
lial cell layer and with superior sensitivity as compared for
instance with enzymatic assays for the content of PGE2
and/or signaling pathway entities, most often determined
Table 2 Percentage drop in total COX-induced short circuit current
by selective inhibitors, COX-1 (SC-560) and COX-2 (Celecoxib)
SC-560
Inhibition, SEM (%)
Celecoxib
Inhibition, SEM (%)
p-value
CRN-pts (N/n = 15/26) 68.8 ± 4.5 53.7 ± 5.1 0.035*
Ctrls (N/n = 10/19) 80.6 ± 4.8 52.6 ± 10.3 0.028*
p-value 0.10 0.91
Horizontal p-values to the right show inhibition by SC-560 compared to inhibition
by Celecoxib for CRN-pts and ctrls. Vertical p-values at the bottom show CRN-pts
compared to ctrls for SC-560 inhibition and Celecoxib inhibition. Inhibition
calculated as percentage selective COX-inhibition of total COX-inhibition.
Total COX-inhibition defined as selective COX-inhibition + indomethacin
inhibition. Percentage drop reflects the overall decreased activity. CRN-pts
represent values for biopsies from colorectal neoplasia patients and ctrls
values are for biopsies from patients without colorectal neoplasia. N = number of
patients, n = number of biopsies, in parenthesis (N/n). * p-value < 0.05
Table 3 COX-1 and COX-2 expression based on real time poly-
merase chain reaction in colonic biopsies from CRN-pts and
ctrls
COX-1 expression,
SEM
COX-2 expression,
SEM
p-value
CRN-pts
(N/n = 11/11)
0.024 ± 0.003 0.007 ± 0.002 0.012 *
Ctrls
(N/n = 7/7)
0.020 ± 0.003 0.005 ± 0.002 < 0.001 *
p-value 0.24 0.43
Horizontal p-values to the right compare COX-1 expression with COX-2 expression
for CRN-pts and ctrls. Vertical p-values at the bottom compare CRN-pts with ctrls for
COX-1 and COX-2 expression. Total or combined expression of COX enzyme is
defined as expression of COX-1 + COX-2. The combined COX expression was 0.015
± 0.003 for CRN-pts and 0.012 ± 0.003 for ctrls; p= 0.35. CRN-pts represent values for
biopsies from colorectal neoplasia patients and ctrls values are for biopsies from
patients without colorectal neoplasia. N= number of patients, n= number of
biopsies, in parenthesis (N/n). * p-value < 0.05
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for the entire mucosa, with low accuracy and thus limited
by indirect congruency with epithelial functionality.
COX-1 and COX-2 isozymes
A previous functional study from our laboratory re-
ported an increased total COX activity in endoscopic
normal appearing mucosa from patients with diagnosis
of CRN [9]. The present study supports this observation,
since the combined activity of COX-1 and COX-2 in co-
lonic mucosa is significantly increased with CRN and
cancer, though neither COX-1 nor COX-2 alone showed
a significantly augmented activity.
Up-regulation of COX-2 is associated with increased
cell adhesion, phenotypic changes, resistance to apop-
tosis and tumor angiogenesis [13–17]. These changes
are possibly due to a raised prostaglandin E2 production,
a notion supported by two laboratories, where Eberhart
et al. found levels of prostaglandin E2 to be 3-4 fold in-
creased in CRC tissue [18, 19]. PGE2 is known to inhibit
apoptosis, to stimulate both tumor growth and angio-
genesis and to act as an immunosuppressant in patients
with CRC [13, 20, 21]. Even though COX-2 is a well-
known enhancer of carcinogenesis in CRC, it has been
proposed that both COX-1 and COX-2 pathways are in-
volved in intestinal tumorigenesis [17]. This statement is
strongly supported by experimental animal studies as
the loss of either COX-1 or COX-2 genes blocks intes-
tinal polyposis in mouse models of familial adenomatous
polyposis by approximately 90% [22, 23].
Knowledge about overexpression of various enzymes
in neoplastic tissue is well established, but our study
additionally indicates that NSAID-sensitive mechanisms
are over-activate not only in neoplastic tissue, but also in
endoscopic normal appearing mucosa in CRN-pts,
thereby representing tissue with an predisposed potential
condition for neoplastic development.
In the present study, expressional levels of constitutive
COX-1 were statistically higher compared to COX-2 in
both CRN-pts and ctrls, Table 3 horizontal p-values.
This finding may be contrasted by considerations about
the characteristics of the two isozymes. COX-1 gene is
considered the “housekeeping enzyme” and is highly and
constitutively expressed in platelets and in gastric epi-
thelial cells. In the latter, it helps in cytoprotection
through the generation of prostanoids [24, 25]. In con-
trast, the COX-2 enzyme is inducible by many factors:
e.g., bacterial endotoxins, cytokines and growth factors.
Accordingly, the COX-2 activity is typically transient
[26]. Of note, this differentiation between the cyclooxy-
genase isozymes, more than often turns out to be too
simplistic [27, 28].
COX-1 detection and tuft cells
One of three employed COX-1 antibodies stained the
biopsy mucosa specifically in sporadic epithelial cells. By
double-staining for COX-1 and enteroendocrine cells
(EECs), we could exclude a labeling of EECs, Fig. 3c.
Therefore, we rationalized that the COX-1 staining
Fig. 3 Immunohistochemical staining of colonic mucosa with cyclooxygenase (COX) subtype specific antibodies in patients with colorectal neoplasia.
a COX-2 immunohistochemical staining appears localized to the cytoplasm of absorptive cells (yellow arrows). No staining is seen in goblet cells
(red arrows). A pericryptal stromal cell is marked (green arrow). b COX-1 immunohistochemical staining, here with antibody sc-1752, appears to stain
morphological appearing tuft cells (red arrows) and in the lamina propria proposedly myofibroblasts (green arrow). c Fluorescence double labeling
shows no co-localization between COX-1 (green) and specific markers for endocrine cells (red). Arrows point at COX-1 positive tuft cells. Subfigures 1,
2, 3, 5 and 7 have proportions of 100 μm per centimeter, subfigures 4 and 6 have proportions of 50 μm per centimeter. 1: Glucagon-like peptide-1, 2:
Somatostatin, 3: Gastric Inhibitory Polypeptide, 4: Proprotein Convertase-1, 5: Proprotein Convertase-2, 6: Serotonin, 7: Chromogranin A
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detected tuft cells as also concluded in several mouse
colon studies with COX-1 immunostaining [12, 29–31].
These cells (also known as brush cells) have previously
been found in endoderm-derived epithelia [12]. Tuft
cells have long and blunt microvilli with a protruding
root system along a well-built tubulovesicular system in
the cytoplasm near the nucleus [32]. Fairly recently, tuft
cells have been acknowledged as an important part of
the intestinal lining with an immunological role to play
in helminthic infections [33], while a more strict com-
bination of specific tuft cell markers is still debated [12,
29, 33, 34]. Functional studies of tuft cells related to hu-
man colon cancer are still scarce [35], while colonic tuft
cells appear related to the defense against worm infec-
tions [12]. To conclude, the COX-1-dependent PGE2
production in human colonic mucosa seems likely
derived solely from epithelial tuft cells and probably as
well supplied from subepithelial immune cells, which
also stained with COX-1 antibody, data not shown. This
proposal and a quantification of tuft cells in CRN-pts
compared with ctrls, requires a separate study.
PGE2-producing stromal cells, colored by COX-1 and
COX-2 antibodies in Fig. 3a, b, and c, are possibly myo-
fibroblast, as suggested by Powell et al. [36], immune
cells, mesenchymal stem cells and other non-identified
stromal cells. As mentioned in the Result section, there
is also an expression of the COX-1 protein in solitary
subepithelial myofibroblast-like cells of human colonic
mucosa, although with a much fainter coloring than for
other stromal cells and epithelial tuft cells shown in
Fig. 3b and c. This finding of COX-1 in subepithelial
myofibroblasts is in line with earlier findings in the
mouse small intestine and of myofibroblasts cultured
from a mucosal biopsy of human neonatal colon [36,
37]. Of note, some of the produced PGE2 in human
colonic mucosa is most likely also produced by stromal
myofibroblasts as demonstrated for cultured colonic
myofibroblasts from mice [38].
Study population
Due to differences in the basic characteristics of our two
patient groups, our study presents certain potential limi-
tations. BMI and age were apparently slightly higher in
the CRN study population. These observations are in
line with obesity and increasing age being known risk
factors for developing CRN and CRC [39]. Furthermore,
SCC inhibition with amiloride and stimulation with
theophylline differed between the study groups, Table 1.
The colonic SCC response to amiloride is known for its
variability and dependence on food ingredients, e.g., salt
intake [40, 41]. The observed difference in SCC induced
by amiloride can therefore be an unrelated variation in
salt intake in our human study cohort and needs to be
clarified in future studies. The characteristic of a
significantly larger stimulatory effect of theophylline in
CRN-pts is currently under study in our laboratory with
results indicating lower SCC response to phospho-
diesterase 4, PDE4, inhibition in colonic mucosa from
CRN-pts. The increased theophylline response found in
CRN-pts in this study, Table 1, could therefore also be a
result of compensatory elevated phosphodiesterase activ-
ity in patients with CRN [42].
Perspective on the use of aspirin and other NSAIDs
In the last decade, the mechanism of daily low-dose as-
pirin as a CRN-preventive measure has been questioned.
Originally, the benefits of low-dose aspirin intake were
thought primarily due to its COX enzyme inhibitor ef-
fects [2, 43]. Also, the recently published USPSTF’s
recommendation for aspirin use in the prevention of
CRN and CRC has not yet reached a general endorse-
ment, as additional groupings, conditions and more
evidence are still needed for a broad acceptance [5]. Our
study here adds experimental human data, which sup-
port medication with non-selective COX-inhibitors for
the prevention and/or treatment of CRN and CRC.
The subject of aspirin supplementation is now further
complicated by recent realizations about the mecha-
nisms behind beneficial effects of aspirin treatment
involving integrated and intracellular multi-signaling
pathways, such as pathological Wnt-beta-catenin and
MAPKinase signaling as well as dysregulated non-coding
long-RNA epigenetics and platelet functions [3, 6, 44].
Notwithstanding, a supposed major CRC prevention
mechanism is still the inhibition of COX enzymes elic-
ited by aspirin and other NSAID drugs. The level of
mucosal PGE2 is lifted with CRN due to increased COX
activity and possibly also reduced catabolism by not of a
15-hydroxy-prostaglandin-dehydrogenase PGE2 break-
down [31]. NSAID-inhibition in effect reduces a lifted
PGE2 level presumed to drive an immunosuppression or
immune evasion, that establishes an oncogenic milieu [45].
Therefore, it is still important to study the PGE2 me-
tabolism, including steps of its synthesis and catabolism,
as well as its pertinent signaling pathways. And also,
bring these studies from the culture dish and animal
cage to human individuals for a comparison between
these PGE2 parameters obtained from normal colonic
mucosa of affected patients and controls. The research
presented here is such a study and has revealed an equal
importance of the two COX enzyme subtypes, COX-1
and COX-2, for the development of CRN, as the com-
bined COX-1 and COX-2 displayed higher activity in
CRN-pts. As the study is a pilot study with few partici-
pants, it certainly warrants confirmation by similar
studies with much larger cohort numbers.
Full consensus for the use of daily low-dose aspirin to
prevent CRC development, in the USPSTF
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recommendation, is still limited by uncertainties about
the balance between advantageous and adverse effects
for prophylactic use of NSAID chemo-preventive medi-
cine against colorectal neoplasia [5]. This is due to vari-
able setups and outcomes of several large clinical trials
together involving more than 70,000 test persons.
Furthermore, in this context it is still a hope to obtain
better individualized medication, precision medicine,
and molecular bio-markers for a more accurate assess-
ment of risk stratification [46].
There is an ongoing dramatic development in studies
on the COX-2 downstream-enzyme mPGES-1 (micro-
somal prostaglandin E2 synthase 1) with associated re-
search for its selective and clinically relevant inhibitors.
Discovery of such mPGES-1 inhibitors are intensely
chased for the prevention of COX-2 dependent PGE 2
production and their installment as therapeutics [47].
While we wait for clinically approved mPGES-1 inhibi-
tors for CRN, our study rather point to a possible use of
low-dose non-specific COX inhibitors. Other alternative
approach for treating CRN and CRC involving PGE2
may come from the bourgeoning studies on the gut
microbiota, where the microorganism Fusobacterium
nucleatum is linked with development of CRC and sus-
pected of inducing microRNA-21 to increase the levels
of IL-10 and prostaglandin E2 [48, 49].
Conclusions
We find that COX-1 and COX-2 jointly contribute to
COX-overactivity in colonic mucosa from patients with
colorectal neoplasia. The clinical implications of the
study are important for possible medical treatment of
colorectal neoplasia with COX inhibitors, as it points to
the use of non-selective COX inhibitors rather than spe-
cific COX-2 inhibitors. Immunohistochemically, COX-2
localizes to the cytoplasm of absorptive cells, while cells
morphologically appearing like endocrine cells, non-
identifiable with ordinary endocrine cell markers, seem
to be COX-1 positive. However, for the normal epithe-
lium of human colon, confirmation of COX-1 enzyme
localization needs additional studies.
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